Biocad
Clinical trials sponsored by Biocad, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New antibody drug shows promise for tough ulcerative colitis cases Results expected Jan 2027 (estimated)
- One-Shot gene therapy could free hemophilia b patients from frequent injections Results expected Apr 2027 (estimated)
- New hope for Crohn's? experimental antibody BCD-261 enters Mid-Stage trial Results expected May 2027 (estimated)
-
Can a new injection match the standard for dialysis anemia?
Disease control OngoingThis trial tests whether a new drug called BCD-131 can manage anemia in people with chronic kidney disease who are on dialysis. Anemia is a common complication where the body doesn't make enough red blood cells, causing fatigue and weakness. The study compares BCD-131, given once…
Phase 3 • Sponsor: Biocad • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New antibody drug aims to halt Scleroderma's grip
Disease control OngoingThis Phase 3 trial tests whether the drug divozilimab can reduce skin thickening and protect lung function in people with systemic scleroderma, a rare autoimmune disease. About 152 adults and teens with active disease will receive either the drug or a placebo. The study is double…
Phase 3 • Sponsor: Biocad • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New biologic drug netakimab tested in kids with psoriasis
Disease control OngoingThis phase 3 trial tests the drug netakimab in children aged 6 and older with moderate to severe plaque psoriasis. The study compares netakimab to a placebo and also includes an open-label group receiving adalimumab. The main goal is to see if netakimab improves skin symptoms, me…
Phase 3 • Sponsor: Biocad • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC